Posted by Michael Wonder on 17 Mar 2021
Health Canada approves new indication for lung cancer treatment option Alunbrig
17 March 2021 - First-line indication offers Canadians with advanced lung cancer new treatment options.
Takeda is pleased to announce that Health Canada has issued Alunbrig (brigatinib) marketing authorisation without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive locally advanced or metastatic non-small cell lung cancer.
The approval is based on results from the phase 3 ALTA-1L trial which evaluated 275 patients and showed that once-daily Alunbrig was superior to crizotinib on measures of efficacy and tolerability making it a promising first-line treatment option.
